ctDNA and CTCs in Liquid Biopsy - Current Status and Where We Need to Progress

Martin H D Neumann; Sebastian Bender; Thomas Krahn; Thomas Schlange

doi:10.1016/j.csbj.2018.05.002

ctDNA and CTCs in Liquid Biopsy - Current Status and Where We Need to Progress

Comput Struct Biotechnol J. 2018 Jun 1:16:190-195. doi: 10.1016/j.csbj.2018.05.002. eCollection 2018.

Authors

Martin H D Neumann¹, Sebastian Bender², Thomas Krahn¹, Thomas Schlange¹

Affiliations

¹ Bayer AG, Pharmaceutical Division, Biomarker Research, Wuppertal, Germany.
² Bayer AG, Pharmaceutical Division, Translational Assay Technology, Berlin, Germany.

Abstract

We discuss the current status of liquid biopsy and its advantages and challenges with a focus on pre-analytical sample handling, technologies and workflows. The potential of circulating tumor cells and circulating tumor DNA is pointed out and an overview of corresponding technologies is given.

Keywords: Circulating tumor DNA; Circulating tumor cells; Liquid biopsy; Pre-analytical handling; Technology overview.

Publication types

Review